SOTIO a.s.

SOTIO a.s. is rated 3 out of 5 in the category biotechnology. Read and write reviews about SOTIO a.s.. SOTIO is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and has significant manufacturing and regulatory expertise in autologous cellular therapies. The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy based on dendritic cells. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products. SOTIO is also collaborating with NBE-Therapeutics (Switzerland) on the development of novel antibody-drug conjugate products (ADC), with Cytune Pharma (France) on developing novel IL15-based immunotherapies for the treatment of cancer, with LDC and the Max Planck Society (Germany) on an oncology program addressing a novel target in tumor metabolism and with MaveriX (USA) on targeted small-molecule cancer chemo-immunotherapeutics. SOTIO also recently initiated a Phase I/Ib clinical trial with interleukin-15 superagonist SO-C101. International team of SOTIO includes more than 300 employees of 18 nationalities, facilities in Europe, the United States, China and Russia and in-house capabilities needed for research, clinical development and marketing of novel therapeutics. Member of PPF Group www.ppf.eu